psalexa
logo

Cerebrovascular Disease Therapeutics Pipeline Analysis

Cerebrovascular Disease Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11223
Available Format:

Cerebrovascular disease also known as stroke, is a condition caused by cerebral ischemia or haemorrhage. Ischemic events are further classified on the basis of occurrences of (in vertebrobasilar or carotid distribution) and duration of symptoms. Facial weakness, vertigo, dysphagia, diplopia, dysarthria, gait ataxia, hemisensory numbness, hemiparesis, limb dysmetria, cortical blindness, and bilateral weakness and numbness are some of the symptoms observed in the patients with ischemic stroke. Cerebrovascular disease can be treated by medications such as; antiplatelets, blood thinners, antihypertensives, and anti-diabetic medications. Bayer AS is in the process of developing rivaroxaban as a factor IXa inhibitors for the treatment of cerebrovascular disease. Boehringer Ingelheim GmbH is in the process of developing alteplase as a plasminogen activator for the treatment of the disease. Some of the companies having a pipeline of cerebrovascular disease include Bayer AG, NoNO Inc., F Hoffmann-La Roche AG and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry